AngioDynamics Q1: Sales +12%, margins widen and loss narrows; cash burn and legal risks

AngioDynamics, Inc. (NASDAQ: ANGO) - Quick corporate snapshot
* Reporting period: three months ended August 31, 2025 (Form 10‑Q).
* Business: diversified medical technology (two segments: Med Tech and Med Device).

Key financials (three months ended Aug 31, 2025 vs Aug 31, 2024)
* Net sales: $75,711K vs $67,491K (+$8,220K; +12.2%).
* Cost of sales (ex intangibles): $33,854K vs $30,767K.
* Gross margin: $41,857K vs $36,724K; margin 55.3% vs 54.4% (+90 bps).
* Operating loss: $(10,656)K vs $(13,098)K (improvement).
* Net loss: $(10,903)K vs $(12,798)K (improvement of $1.9M).
* Loss per share: $(0.26) vs $(0.31).
* Weighted average shares: 41,174K vs 40,653K.
* Cash & cash equivalents: $38,762K (Aug 31, 2025) vs $55,893K (May 31, 2025).

Income statement - Positives
* Revenue growth: total sales up 12.2%; Med Tech +26.1% (Auryon, thrombus platforms, NanoKnife) and Med Device +2.3%.
* Gross margin expansion: consolidated margin up 90 bps to 55.3% driven by volume, price and product mix (+$6.6M impact).
* Operating and net loss narrowed vs prior year quarter despite higher operating spend - operating loss improved by ~$2.4M and net loss improved by $1.9M.
* R&D largely stable ($6,417K), showing continued investment without material jump in spend.

Income statement - Negatives
* Operating expenses up: total operating expenses $52,513K vs $49,822K (+$2.7M). Selling & marketing rose $2.5M; G&A rose $1.58M - pressure on operating leverage.
* Other income turned unfavorable: other income (expense), net was $(182)K vs $433K previously (loss of interest income primarily).
* Acquisition/restructuring/other items still meaningful: $2.758M this quarter (plant closure, legal, severance). Total restructuring charges to date $25.6M.
* Tariffs and production issues reduced gross margin impact (tariffs ≈ -$1.7M).
* Share‑based compensation elevated: $4.47M (non‑cash) in the quarter, up from $3.2M.

Balance sheet & cash flow highlights
* Total assets: $265,642K (Aug 31, 2025).
* Total liabilities: $86,787K; stockholders' equity: $178,855K.
* Inventories: $62,255K; inventory reserve $4.6M.
* Accounts receivable, net: $42,643K.
* Intangible assets, net: $68,380K; amortization expense $2.65M this quarter.
* Cash used in operating activities: $(15,914)K this quarter (improved from $(18,253)K prior year).
* Revolving credit facility: $25.0M facility in place; $0 outstanding at Aug 31, 2025. $13.3M of share repurchase authorization remains available.

Operational items, legal and risks
* Port product litigation: ~219 product liability claims consolidated in SD California - ongoing exposure.
* Settlement/payment obligations with Becton Dickinson (BD): one‑time $7.0M (portion paid) and annual minimum payments of $2.5M (company paid $2.5M in the quarter). Payables recorded: $2.4M current and $6.7M long‑term.
* Credit facility covenant: availability subject to an initial $5M block until a fixed charge coverage ratio >1.10x is demonstrated. Facility maturity two years.
* Restructuring: plant closure and manufacturing footprint optimization continuing; recorded $2.345M plant closure expense this quarter; remaining restructuring expected into FY2026.
* Tax position: full valuation allowance on U.S. deferred tax assets - no release recognized; effective tax rate ~ (0.6)% this quarter.
* Backlog modest: $0.4M.

What matters next (near-term catalysts & monitoring)
* Sales momentum in Med Tech (Auryon, NanoKnife) and durable improvement in Med Device - watch next quarter sales and backlog trends.
* Operating expense control - monitor S&M and G&A cadence versus revenue growth for margin recovery.
* Cash burn / operating cash flow - company used $15.9M in operations this quarter; cash fell ~$17.1M - watch liquidity and any borrowings on the revolver.
* Legal outcomes and contingent payments (BD appeal oral argument Oct 8, 2025) and the 219 port claims - material for liabilities and cash if adverse.
* Restructuring progress and expected cost reductions from outsourcing transitions (timing and realized savings vs guidance).

Bottom line: AngioDynamics (NASDAQ: ANGO) delivered solid top‑line growth and improved gross margin in Q1 FY2026 and narrowed its loss, driven by Med Tech strength. However, free cash flow remains negative, operating expenses and restructuring/legal costs are still weighing on results, and material legal/contingent liabilities and restructuring execution are the main downside risks to monitor.